Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders

Biomolecules and Therapeutics

Volumn 20, Issue 2, 2012, Pages 133-143

  Kim, Yoon Seong ^a   Joh, Tong H ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Matrix metalloproteinases; Microglia; MMP 3; Neurodegenerative disorders; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; ISCHEMIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84862701042     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2012.20.2.133     Document Type: Article

References (137)

1. Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Opdenakker, G. and Sorokin, L. M. (2006) Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007-1019.
2. Agrawal, S. M., Lau, L. and Yong, V. W. (2008) MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51.
3. Aldonyte, R., Brantly, M., Block, E., Patel, J. and Zhang, J. (2009) Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp. Lung Res. 35, 59-75.
4. Allan, J. A., Docherty, A. J., Barker, P. J., Huskisson, N. S., Reynolds, J. J. and Murphy, G. (1995) Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem. J. 309, 299-306.
5. Asahi, M., Asahi, K., Jung, J. C., del Zoppo, G. J., Fini, M. E. and Lo, E. H. (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20, 1681-1689.
6. Asahi, M., Sumii, T., Fini, M. E., Itohara, S. and Lo, E. H. (2001) Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport. 12, 3003-3007.
7. Auble, D. T. and Brinckerhoff, C. E. (1991) The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fi- broblasts. Biochemistry. 30, 4629-4635.
8. Avolio, C., Ruggieri, M., Giuliani, F., Liuzzi, G. M., Leante, R., Riccio, P., Livrea, P. and Trojano, M. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136, 46-53.
9. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q. and Iwatsubo, T. (1998) Aggregation of alphasynuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
10. Backstrom, J. R., Miller, C. A. and Tökés, Z. A. (1992) Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58, 983-992.
11. Bannikov, G. A., Karelina, T. V., Collier, I. E., Marmer, B. L. and Goldberg, G. I. (2002) Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 277, 16022-16027.
12. Becker, J. W., Marcy, A. I., Rokosz, L. L., Axel, M. G., Burbaum, J. J., Fitzgerald, P. M., Cameron, P. M., Esser, C. K., Hagmann, W. K., Hermes, J. D. and Springer, J. P. (1995) Stromelysin-1: threedimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 4, 1966-1976.
13. Benesová, Y., Vasku, A., Novotná, H., Litzman, J., Stourac, P., Beránek, M., Kadanka, Z. and Bednarík, J. (2009) Matrix metalloproteinase- 9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 15, 316-322.
14. Bode, W. (1995) A helping hand for collagenases: the haemopexin-like domain. Structure. 3, 527-530.
15. Bode, W., Gomis-Rüth, F. X. and Stöckler, W. (1993) Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 331, 134-140.
16. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M., Oostra, B. A. and Heutink, P. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299, 256-259.
17. Bozdagi, O., Nagy, V., Kwei, K. T. and Huntley, G. W. (2007) In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J. Neurophysiol. 98, 334-344.
18. Campbell, B. C., McLean, C. A., Culvenor, J. G., Gai, W. P., Blumbergs, P. C., Jäkälä, P., Beyreuther, K., Masters, C. L. and Li, Q. X. (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76, 87-96.
19. Candelario-Jalil, E., Yang, Y. and Rosenberg, G. A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 158, 983-994.
20. Cañete Soler, R., Gui, Y. H., Linask, K. K. and Muschel, R. J. (1995) MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Brain Res. Dev. Brain Res. 88, 37-52.
21. Catrina, A. I., Lampa, J., Ernestam, S., af Klint, E., Bratt, J., Klareskog, L. and Ulfgren, A. K. (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford). 41, 484-489.
22. Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., Anthony, D. C., Adams, S. E. and Gearing, A. J. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161.
23. Chang, D. I., Hosomi, N., Lucero, J., Heo, J. H., Abumiya, T., Mazar, A. P. and del Zoppo, G. J. (2003) Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23, 1408-1419.
24. Chin, J. R., Murphy, G. and Werb, Z. (1985) Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J. Biol. Chem. 260, 12367-12376.
25. Cho, K. O., La, H. O., Cho, Y. J., Sung, K. W. and Kim, S. Y. (2006) Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J. Neurosci. Res. 83, 285-291.
26. Choi, D. H., Hwang, O., Lee, K. H., Lee, J., Beal, M. F. and Kim, Y. S. (2011a) DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. Antioxid. Redox. Signal. 14, 2137-2150.
27. Choi, D. H., Kim, Y. J., Kim, Y. G., Joh, T. H., Beal, M. F. and Kim, Y. S. (2011b) Role of matrix metalloproteinase 3-mediated alphasynuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286, 14168-14177.
28. Choi, D. H., Kim, E. M., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., Flint Beal, M. and Hwang, O. (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J. Neurochem. 106, 405-415.
29. Choi, D. H., Kim, E. M., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., Flint Beal, M. and Hwang, O. (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J. Neurochem. 106, 405-415.
30. Cossins, J. A., Clements, J. M., Ford, J., Miller, K. M., Pigott, R., Vos, W., Van der Valk, P. and De Groot, C. J. (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta. Neuropathol. 94, 590-598.
31. Cuadrado, E., Rosell, A., Borrell-Pagès, M., García-Bonilla, L., Hernández-Guillamon, M., Ortega-Aznar, A. and Montaner, J. (2009) Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J. Cereb. Blood Flow Metab. 29, 398-410.
32. Cuzner, M. L., Gveric, D., Strand, C., Loughlin, A. J., Paemen, L., Opdenakker, G. and Newcombe, J. (1996) The expression of tissuetype plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55, 1194-1204.
33. Edwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, A. J., Angel, P. and Heath, J. K. (1987) Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6, 1899-1904.
34. Eguchi, T., Kubota, S., Kawata, K., Mukudai, Y., Uehara, J., Ohgawara, T., Ibaragi, S., Sasaki, A., Kuboki, T. and Takigawa, M. (2008) Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol. Cell Biol. 28, 2391-2413.
35. Fainardi, E., Castellazzi, M., Tamborino, C., Trentini, A., Manfrinato, M. C., Baldi, E., Tola, M. R., Dallocchio, F., Granieri, E. and Bellini, T. (2009) Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult. Scler. 15, 547-554.
36. Forsyth, P. A., Wong, H., Laing, T. D., Rewcastle, N. B., Morris, D. G., Muzik, H., Leco, K. J., Johnston, R. N., Brasher, P. M., Sutherland, G. and Edwards, D. R. (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1- MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer. 79, 1828-1835.
37. Freise, C., Erben, U., Muche, M., Farndale, R., Zeitz, M., Somasundaram, R. and Ruehl, M. (2009) The alpha 2 chain of collagen type VI sequesters latent proforms of matrix-metalloproteinases and modulates their activation and activity. Matrix Biol. 28, 480-489.
38. Gasche, Y., Copin, J. C., Sugawara, T., Fujimura, M. and Chan, P. H. (2001) Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21, 1393-1400.
39. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M. and Woolley, K. (1994) Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 370, 555-557.
40. Giuliani, F., Fu, S. A., Metz, L. M. and Yong, V. W. (2005) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol. 165, 83-91.
41. Gross, J. and Lapiere, C, M. (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA. 48, 1014-1022.
42. Gu, Z., Cui, J., Brown, S., Fridman, R., Mobashery, S., Strongin, A. Y. and Lipton, S. A. (2005) A highly specific inhibitor of matrix metalloproteinase- 9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401-6408.
43. Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C. and Lipton, S. A. (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 297, 1186-1190.
44. Hewson, A. K., Smith, T., Leonard, J. P. and Cuzner, M. L. (1995) Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44, 345-349.
45. Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C. and Wagner, S. (2010) Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. International psychogeriatrics / IPA 22: 966-972
46. Hu, J., Van den Steen, P. E., Sang, Q. X. and Opdenakker, G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498.
47. Ip, Y. C., Cheung, S. T. and Fan, S. T. (2007) Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol. Carcinog. 46, 225-230.
48. Ishiguro, N., Ito, T., Obata, K., Fujimoto, N. and Iwata, H. (1996) Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J. Rheumatol. 23, 1599-1604.
49. Ito, S., Kimura, K., Haneda, M., Ishida, Y., Sawada, M. and Isobe, K. (2007) Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp. Gerontol. 42, 532-537.
50. Joo, S. H., Kwon, K. J., Kim, J. W., Kim, J. W., Hasan, M. R., Lee, H. J., Han, S. H. and Shin, C. Y. (2010) Regulation of matrix metalloproteinase- 9 and tissue plasminogen activator activity by alphasynuclein in rat primary glial cells. Neurosci. Lett. 469, 352-356.
51. Kheradmand, F., Werner, E., Tremble, P., Symons, M. and Werb, Z. (1998) Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science. 280, 898-902.
52. Kim, E. M. and Hwang, O. (2011) Role of matrix metalloproteinase-3 in neurodegeneration. J. Neurochem. 116, 22-32.
53. Kim, K. S., Kim, H. Y., Joe, E. H. and Jou, I. (2008) Matrix metalloproteinase- 3 induction in rat brain astrocytes: focus on the role of two AP-1 elements. Biochem. J. 410, 605-611.
54. Kim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y. J., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., Kim, S. Y., Hong, J. S., Beal, M. F. and Joh, T. H. (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 21, 179-187.
55. Kim, Y. S., Kim, S. S., Cho, J. J., Choi, D. H., Hwang, O., Shin, D. H., Chun, H. S., Beal, M. F. and Joh, T. H. (2005) Matrix metalloproteinase- 3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701-3711.
56. Korzus, E., Nagase, H., Rydell, R. and Travis, J. (1997) The mitogenactivated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J. Biol. Chem. 272, 1188-1196.
57. Kwan, J. A., Schulze, C. J., Wang, W., Leon, H., Sariahmetoglu, M., Sung, M., Sawicka, J., Sims, D. E., Sawicki, G. and Schulz, R. (2004) Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADPribose) polymerase (PARP) in vitro. FASEB J. 18, 690-692.
58. Larsen, P. H., DaSilva, A. G., Conant, K. and Yong, V. W. (2006) Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 26, 2207-2214.
59. Larsen, P. H., Wells, J. E., Stallcup, W. B., Opdenakker, G. and Yong, V. W. (2003) Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23, 11127-11135.
60. Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A. and Price, D. L. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99, 8968-8973.
61. Lee, R., Kermani, P., Teng, K. K. and Hempstead, B. L. (2001) Regulation of cell survival by secreted proneurotrophins. Science. 294, 1945-1948.
62. Lee, S. R., Kim, H. Y., Rogowska, J., Zhao, B. Q., Bhide, P., Parent, J. M. and Lo, E. H. (2006) Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci. 26, 3491-3495.
63. Li, W., Chang, L., Rong, Z. and Liu, W. (2011) Retinoic aacid diminished the expression of MMP-2 in hyperoxia-exposed premature rat lung fibroblasts through regulating mitogen-activated protein kinases. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 31, 251-257.
64. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L. and Lee, M. K. (2005) Aggregation promoting C-terminal truncation of alphasynuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA. 102, 2162-2167.
65. Limb, G. A., Matter, K., Murphy, G., Cambrey, A. D., Bishop, P. N., Morris, G. E. and Khaw, P. T. (2005) Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am. J. Pathol. 166, 1555-1563.
66. Liu, C. W., Giasson, B. I., Lewis, K. A., Lee, V. M., Demartino, G. N. and Thomas, P. J. (2005) A precipitating role for truncated alphasynuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670-22678.
67. Liu, X., Manzano, G., Lovett, D. H. and Kim, H. T. (2010) Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem. Biophys. Res. Commun. 396, 219-223.
68. Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. and Beal, M. F. (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp. Neurol. 178, 13-20.
69. Lorenzl, S., Albers, D. S., Relkin, N., Ngyuen, T., Hilgenberg, S. L., Chirichigno, J., Cudkowicz, M. E. and Beal, M. F. (2003) Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 43, 191-196.
70. Maeda, A. and Sobel, R. A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55, 300-309.
71. Marchenko, N. D., Marchenko, G. N., Weinreb, R. N., Lindsey, J. D., Kyshtoobayeva, A., Crawford, H. C. and Strongin, A. Y. (2004) Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell. Biol. 36, 942-956.
72. Matrisian, L. M., Glaichenhaus, N., Gesnel, M. C. and Breathnach, R. (1985) Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J. 4, 1435-1440.
73. Matsuno, H., Yudoh, K., Watanabe, Y., Nakazawa, F., Aono, H. and Kimura, T. (2001) Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J. Rheumatol. 28, 22-28.
74. McCarthy, S. M., Bove, P. F., Matthews, D. E., Akaike, T. and van der Vliet, A. (2008) Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch. Biochemistry. 47, 5832-5840.
75. McClain, J. A., Phillips, L. L. and Fillmore, H. L. (2009) Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci. Lett. 460, 27-31.
76. Meighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. L., Zornes, P. A., Wright, J. W. and Harding, J. W. (2006) Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 96, 1227-1241.
77. Metz, L. M., Zhang, Y., Yeung, M., Patry, D. G., Bell, R. B., Stoian, C. A., Yong, V. W., Patten, S. B., Duquette, P., Antel, J. P. and Mitchell, J. R. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 55, 756.
78. Miller, D. W., Ahmad, R., Hague, S., Baptista, M. J., Canet-Aviles, R., McLendon, C., Carter, D. M., Zhu, P. P., Stadler, J., Chandran, J., Klinefelter, G. R. Blackstone, C. and Cookson, M. R. (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588-36595.
79. Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G. and Love, S. (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240-252.
80. Mohanam, S., Wang, S. W., Rayford, A., Yamamoto, M., Sawaya, R., Nakajima, M., Liotta, L. A., Nicolson, G. L., Stetler-Stevenson, W. G. and Rao, J. S. (1995) Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin. Exp. Metastasis. 13, 57-62.
81. Ogier, C., Bernard, A., Chollet, A. M., LE Diguardher, T., Hanessian, S., Charton, G., Khrestchatisky, M. and Rivera, S. (2006) Matrix metalloproteinase- 2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia. 54, 272-284.
82. Ohnishi S. and Takano, K. (2004) Amyloid fibrils from the viewpoint of protein folding. Cell Mol. Life Sci. 61, 511-524.
83. Okamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A. and Maeda, H. (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276, 29596-29602.
84. Opdenakker, G., Dillen, C., Fiten, P., Martens, E., Van Aelst, I., Van den Steen, P. E., Nelissen, I., Starckx, S., Descamps, F. J., Hu, J., Piccard, H., Van Damme, J., Wormald, M. R., Rudd, P. M. and Dwek, R. A. (2006) Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta. 1760, 610-615.
85. Osteen, K. G., Bruner, K. L. and Sharpe-Timms, K. L. (1996) Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin. Reprod. Endocrinol. 14, 247-255.
86. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I. and Nussbaum, R. L. (1997) Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science. 276, 2045-2047.
87. Rao, J. S., Yamamoto, M., Mohaman, S., Gokaslan, Z. L., Fuller, G. N., Stetler-Stevenson, W. G., Rao, V. H., Liotta, L. A., Nicolson, G. L. and Sawaya, R. E. (1996) Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. Exp. Metastasis. 14, 12-18.
88. Reunanen, N., Westermarck, J., Häkkinen, L., Holmström, T. H., Elo, I., Eriksson, J. E. and Kähäri, V. M. (1998) Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stressactivated protein kinase pathways. J. Biol. Chem. 273, 5137-5145.
89. Ries, C. and Petrides, P. E. (1995) Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe. Seyler. 376, 345-355.
90. Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J. and Fridman, R. (1994) Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun. 205, 1755-1761.
91. Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H. and Barone, F. C. (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase- 9 reduces infarct size. Stroke. 29, 1020-1030.
92. Rosenberg, G. A., Cunningham, L. A., Wallace, J., Alexander, S., Estrada, E. Y., Grossetete, M., Razhagi, A., Miller, K. and Gearing, A. (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin- 1 and microglia in cell cultures. Brain Res. 893, 104-112.
93. Sang, Q. X., Jin, Y., Newcomer, R. G., Monroe, S. C., Fang, X., Hurst, D. R., Lee, S., Cao, Q. and Schwartz, M. A. (2006) Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr. Top. Med. Chem. 6, 289-316.
94. Sapolsky, A. I., Howell, D. S. and Woessner JF, Jr. (1974) Neutral proteases and cathepsin D in human articular cartilage. The Journal of clinical investigation 53, 1044-1053
95. Sellebjerg, F. and Sørensen, T. L. (2003) Chemokines and matrix metalloproteinase- 9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 61, 347-355.
96. Shin, E. J., Kim, E. M., Lee, J. A., Rhim, H. and Hwang, O. (2012) Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: Relevance to Parkinson's disease. Neurochem. Int. 60, 249-256.
97. Singh, N. K., Quyen, D. V., Kundumani-Sridharan, V., Brooks, P. C. and Rao, G. N. (2010) AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis. J. Biol. Chem. 285, 16830-16843.
98. Si-Tayeb, K., Monvoisin, A., Mazzocco, C., Lepreux, S., Decossas, M., Cubel, G., Taras, D., Blanc, J. F., Robinson, D. R. and Rosenbaum, J. (2006) Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am. J. Pathol. 169, 1390-1401.
99. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature. 388, 839-840.
100. Starckx, S., Van den Steen, P. E., Verbeek, R., van Noort, J. M. and Opdenakker, G. (2003) A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J. Neuroimmunol. 141, 47-57.
101. Steffensen, B., Wallon, U. M. and Overall, C. M. (1995) Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J. Biol. Chem. 270, 11555-11566.
102. Stojic, J., Hagemann, C., Haas, S., Herbold, C., Kühnel, S., Gerngras, S., Roggendorf, W., Roosen, K. and Vince, G. H. (2008) Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci. Res. 60, 40-49.
103. Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S. T., Paik, S. R. and Chung, K. C. (2005) Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 25216-25224.
104. Sung, M. M., Schulz, C. G., Wang, W., Sawicki, G., Bautista-López, N. L. and Schulz, R. (2007) Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J. Mol. Cell Cardiol. 43, 429-436.
105. Szklarczyk, A., Lapinska, J., Rylski, M., McKay, R. D. and Kaczmarek, L. (2002) Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22, 920-930.
106. Tiraboschi, P., Hansen, L. A., Thal, L. J. and Corey-Bloom, J. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 62, 1984-1989.
107. Treadwell, B. V., Neidel, J., Pavia, M., Towle, C. A., Trice, M. E. and Mankin, H. J. (1986) Purification and characterization of collagenase activator protein synthesized by articular cartilage. Arch. Biochem. Biophys. 251, 715-723.
108. Uhm, J. H., Dooley, N. P., Villemure, J. G. and Yong, V. W. (1996) Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin. Exp. Metastasis. 14, 421-433.
109. Ulisse, S., Farina, A. R., Piersanti, D., Tiberio, A., Cappabianca, L., D'Orazi, G., Jannini, E. A., Malykh, O., Stetler-Stevenson, W. G. and D'Armiento, M. (1994) Follicle-stimulating hormone increases the expression of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in prepubertal rat Sertoli cells. Endocrinology. 135, 2479-2487.
110. Vaillant, C., Meissirel, C., Mutin, M., Belin, M. F., Lund, L. R. and Thomasset, N. (2003) MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol. Cell Neurosci. 24, 395-408.
111. Van den Steen, P. E., Van Aelst, I., Hvidberg, V., Piccard, H., Fiten, P., Jacobsen, C., Moestrup, S. K., Fry, S., Royle, L., Wormald, M. R., Wallis, R., Rudd, P. M., Dwek, R. A. and Opdenakker, G. (2006) The hemopexin and O-glycosylated domains tune gelatinase B/ MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 281, 18626-18637.
112. Van Lint, P. and Libert, C. (2007) Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82, 1375-1381.
113. Van Wart, H. E. and Birkedal-Hansen, H. (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87, 5578-5582.
114. Vincenti, M. P. (2001) The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. (2001) Transcriptional and posttranscriptional regulation, signal transduction and celltype- specific expression. Methods Mol. Biol. 151, 121-148.
115. Vincenti, M. P. and Brinckerhoff, C. E. (2007) Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J. Cell Physiol. 213, 355-364.
116. Walker, E. J. and Rosenberg, G. A. (2010) Divergent role for MMP-2 in myelin breakdown and oligodendrocyte death following transient global ischemia. J. Neurosci. Res. 88, 764-773.
117. Wang, W., Sawicki, G. and Schulz, R. (2002a) Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 53, 165-174.
118. Wang, W., Schulze, C. J., Suarez-Pinzon, W. L., Dyck, J. R., Sawicki, G. and Schulz, R. (2002b) Intracellular action of matrix metalloproteinase- 2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 106, 1543-1549.
119. Waubant, E., Goodkin, D. E., Gee, L., Bacchetti, P., Sloan, R., Stewart, T., Andersson, P. B., Stabler, G. and Miller, K. (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 53, 1397-1401.
120. Wenk, G. L. (2003) Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry. 64(Suppl 9), 7-10.
121. Werb, Z. and Reynolds, J. J. (1974) Stimulation by endocytosis of the secretion of collagenase and neutral proteinase from rabbit synovial fibroblasts. J. Exp. Med. 140, 1482-1497.
122. Woo, M. S., Park, J. S., Choi, I. Y., Kim, W. K. and Kim, H. S. (2008) Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem. 106, 770-780.
123. Yamamoto, M., Hirayama, R., Naruse, K., Yoshino, K., Shimada, A., Inoue, S., Kayagaki, N., Yagita, H., Okumura, K. and Ikeda, S. (1999) Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing. Drug Des. Discov. 16, 119-130.
124. Yamamoto, M., Mohanam, S., Sawaya, R., Fuller, G. N., Seiki, M., Sato, H., Gokaslan, Z. L., Liotta, L. A., Nicolson, G. L. and Rao, J. S. (1996) Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 56, 384-392.
125. Yan, C. and Boyd, D. D. (2007) Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 211, 19-26.
126. Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., Hsu, C. Y., Holtzman, D. M. and Lee, J. M. (2006) Matrix metalloproteinase-9 degrades amyloidbeta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574.
127. Yan, W., Zhang, W., Sun, L., Liu, Y., You, G., Wang, Y., Kang, C., You, Y. and Jiang, T. (2011) Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 1411, 108-115.
128. Yang, Y., Candelario-Jalil, E., Thompson, J. F., Cuadrado, E., Estrada, E. Y., Rosell, A., Montaner, J. and Rosenberg, G. A. (2010) Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 112, 134-149.
129. Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W. and Rosenberg, G. A. (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697-709.
130. Ye, H., Cai, P. C., Zhou, Q. and Ma, W. L. (2011) Transforming growth factor-β1 suppresses the up-regulation of matrix metalloproteinase- 2 by lung fibroblasts in response to tumor necrosis factor-α. Wound Repair Regen. 19, 392-399.
131. Yong, V. W. (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6, 931-944.
132. Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R. and Edwards, D. R. (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75-80.
133. Yong, V. W., Zabad, R. K., Agrawal, S., Goncalves Dasilva, A. and Metz, L. M. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci. 259, 79-84.
134. Yoshida, D., Watanabe, K., Takahashi, H., Sugisaki, Y. and Teramoto, A. (2003) Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent. Brain Tumor Pathol. 20, 13-19.
135. Yoshiyama, Y., Asahina, M. and Hattori, T. (2000) Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta. Neuropathol. 99, 91-95.
136. Yushchenko, M., Weber, F., Mäder, M., Schöll, U., Maliszewska, M., Tumani, H., Felgenhauer, K. and Beuche, W. (2000) Matrix metalloproteinase- 9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110, 244-251.
137. Zucker, S., Lysik, R. M., Zarrabi, M. H., Greenwald, R. A., Gruber, B., Tickle, S. P., Baker, T. S. and Docherty, A. J. (1994) Elevated plasma stromelysin levels in arthritis. J. Rheumatol. 21, 2329-2333.